JALRA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, South Africa, Spain.

Active ingredients

The drug JALRA contains one active pharmaceutical ingredient (API):

1	Vildagliptin UNII I6B4B2U96P - VILDAGLIPTIN
	Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion by increasing the endogenous levels of these incretin hormones. The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
	Read more about Vildagliptin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JALRA Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BH02	Vildagliptin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
Discover more medicines within A10BH02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1391408, 1391419, 1391420, 1391431, 1391442, 1391453, 1391464, 1391475, 1391486, 1391497
ES	Centro de información online de medicamentos de la AEMPS	08485003, 08485005
FR	Base de données publique des médicaments	65787998
IT	Agenzia del Farmaco	038997019, 038997021, 038997033, 038997045, 038997058, 038997060, 038997072, 038997084, 038997096, 038997108, 038997110
LT	Valstybinė vaistų kontrolės tarnyba	1035134, 1035135, 1035136, 1035137, 1035138, 1035139, 1035140, 1035141, 1035142, 1035143, 1035144
PL	Rejestru Produktów Leczniczych	100258770
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54465001, W54465002, W54465003, W54465004, W54465005, W54465006, W54465007, W54465008, W54465009, W54465010, W54465011
ZA	Health Products Regulatory Authority	45/21.2/1009